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Abstract
IMPORTANCE Follow-up of participants in randomized trials may be limited by logistic and financial
factors. Some important randomized trials have been extendedwell beyond their original follow-up
period by linkage of individual participant information to routinely collected data held in
administrative records and registries.
OBJECTIVE To perform a scoping review of randomized clinical trials extended by record linkage to
characterize this literature and explore any additional insights into treatment effectiveness provided
by long-term follow-up using record linkage.
DATA SOURCES A literature search in Embase, CINAHL, MEDLINE, and the Cochrane Register of
Controlled Trials was performed for the period January 1, 1945, through November 25, 2016.
STUDY SELECTION Various combinations of search terms were used, as there is no accepted
terminology. Determination of study eligibility and extraction of information about trial
characteristics and outcomes, for both original and extended trial reports, were performed in
duplicate.
DATA EXTRACTIONAND SYNTHESIS Assessment of study eligibility and data extraction were
performed independently by 2 reviewers. All analyses were descriptive.
MAINOUTCOMES ANDMEASURES Outcomes in the pairs of original and extended trials were
categorized according to whether any benefits or harms from interventions were sustained, were
lost, or emerged during long-term follow-up.
RESULTS A total of 113 extended trials were included in the study. Linkage to administrative and
registry data extended follow-up by between 1 and 55 years. Themost common interventions were
pharmaceuticals (47 [41.6%]), surgery (19 [16.8%]), and disease screening (19 [16.8%]). End points
most frequently studied through record linkage includedmortality (88 [77.9%]), cancer (41 [36.3%]),
and cardiovascular events (37 [32.7%]). One hundred four trial extensions (92.0%) were analyzed
according to the original trial randomization. The reports provided details of 155 analyses of study
outcomes. Seventy-four analyses (47.7%) identified statistically significant benefits in the trial
extension phase. In 21 of these (28.4%), benefits were significant only in this period. Null results in
both the original and extended trials were seen in 34 of the analyses (21.9%). Loss of significant
benefits of an intervention were seen in 12 analyses (7.7%). Statistically significant harms were seen
in 16 trial extension analyses (10.3%), and in 14 of these (87.5%), the harms were significant only in
the trial extension phase.
(continued)
Key Points
Question Does follow-up of clinical trial
participants by linkage to routinely
collected data sources provide
important insights into the long-term
benefits and harms of treatment?
Findings This scoping review of the
published literature found only 113 trials
that had been extended by record
linkage. Analysis showed that some
benefits of treatment extend beyond
the trial, and some harms of treatment
only become apparent after the trial is
complete.
Meaning The fate of patients after
participation in clinical trials is a
neglected topic, and the authors
recommend that researchers routinely
request permission from trial
participants to study long-term
treatment effects using linkage to
routinely collected data.
+ Invited Commentary
+ Supplemental content
Author affiliations and article information are
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Abstract (continued)
CONCLUSIONS ANDRELEVANCE Trial extension by linkage to routinely collected data is a versatile
underused approach thatmay add critical insights beyond those of the original trial. Some beneficial
and harmful outcomes of interventions are captured only in the extension phase of
randomized trials.
JAMA Network Open. 2018;1(8):e186019. doi:10.1001/jamanetworkopen.2018.6019
Introduction
Well-conducted randomized clinical trials remain the gold standard for generating estimates of
efficacy, but follow-up times may be restricted by cost and logistical considerations. This reduces the
capacity of trials to quantify long-term outcomes, including uncommon but serious harms of
treatment.1 Trial extension by record linkage enables evaluation of long-term effectiveness of
interventions, including end points that were not specified in the trial protocol.2-4 This has been
aided by improved access to population-scale routinely collected health data sets, which can be
linked to individual-level information held in other available databases long after the trials were
terminated.
Recent examples of this approach include a 25-year follow-up of the Canadian National Breast
Cancer Screening Study, achieved by linkage of trial participants to information held in cancer and
vital statistics registries,5 and a 20-year follow-up of theWest of Scotland Coronary Prevention study,
achieved by linkage to administrative health data.6
There are several reasons for extending randomized trials. Most obvious is a desire to estimate
the long-term benefits of an intervention.7 Extended follow-up may provide information on long-
term harms, for instance the development of secondmalignancies after radiotherapy.8 Follow-up can
enable study of the patterns and outcomes of treatment changes and co-interventions implemented
after trial completion.
It is not clear howmany trials have been extended by record linkage. This scoping review aimed
to assess the frequency with which trial extension studies using routinely collected data have been
performed, characterize the studies, and explore any additional insights they provided into
treatment benefits and harms.
Methods
The protocol for this reviewwas registered in February 2017.9 In conducting the review, we followed
published guidelines and the Preferred Reporting Items for Systematic Reviews andMeta-analyses
(PRISMA) reporting guideline Extension for Scoping Reviews.10-12 The University of Toronto Health
Sciences Research Ethics Board confirmed that reviewwas not required as the study was limited to
published information.
Objectives of the Scoping Review
Our study aims raised several questions: (1) Howmany trials were extended by linkage to routinely
collected data, and has the number increased over time? (2) In which countries were the studies
performed? (3) What medical conditions and interventions were the targets of these initiatives? (4)
Were data analyzed according to randomization? and (5) In what ways did the outcomes seen in the
extended trials provide additional insights into the long-term benefits and harms of the interventions
being studied?
Literature Searching
We confined our search to the published literature in Embase, MEDLINE, CINAHL, and the Cochrane
Register of Controlled Trials for the period January 1, 1945, to November 25, 20169; details are
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provided in eTable 1 in the Supplement. The draft search strategy (for MEDLINE) was developed by 1
of us (L.P.). It was assessed by a second information scientist according to the Peer Review of
Electronic Search Strategies (PRESS) checklist.13 Because this is an emerging area, there are no
dedicated indexing terms, and there was considerable variability in how relevant studies were
described. Our initial scan identified relevant studies that did not refer explicitly to data linkage in
their abstracts. Accordingly, we searched for additional articles using the Related Articles feature in
PubMed for articles included in the scoping review.14 The search strategy was limited to English-
language articles, but there were no other restrictions. From the trial extension reports, we identified
the reports of the original trials. All references were stored and shared using ReferenceManager
version 12.
Study Eligibility andData Extraction
Decisions about eligibility and data extraction (for the original trial and extension reports) were
carried out by 2 independent reviewers. One investigator (T.F.) read all abstracts and full-text reports
and extracted data from all eligible studies. The data extraction instrument was piloted by 2
investigators (T.F. and D.H.), with several modifications before use. To be eligible for full-text
retrieval, trial extension reports had to describe follow-up of participants in a randomized clinical trial
at least 1 year after completion of the trial using record linkage. To be eligible for data extraction, the
study had to report linkage of trial participant information to routinely collected data sources (eg,
vital statistics, disease registry, health administrative data). Studies that used a continuation of the
normal trial follow-up processes or follow-up data obtained only frommedical records at the home
institution were excluded. Differences between reviewers were resolved by discussion. For some
trials, there wasmore than 1 published extension report. In such cases, we used the longest follow-up
study or, in cases where the longest follow-up study involved a subsample, we used the study that
most closely matched the primary trial (in terms of study population, randomization, and the choice
of end points). The information collected from the original and trial extension reports is provided in
eTable 2 in the Supplement.
At all times, we used the end point definitions and analyses reported by authors andmade no
attempt to reclassify or recalculate the values published in the original or extended trial reports.
Categorization of Trial ExtensionOutcomes
We considered several scenarios. A statistically significant advantage of an effective treatment might
still be apparent years after trial completion despite uniform access to therapy, a so-called legacy
effect. Conversely, the treatment benefits might decline over time, for instance in the case of waning
immunity after vaccination. For trials showing apparent equivalence, or a statistically nonsignificant
trend in favor of 1 treatment, similar patterns might be observed in the trial extension period, or an
advantage of 1 treatment might emerge over time because of increased precision of the estimates of
effectiveness. Similar patterns might also be observed for end points that were not specified in the
original trial. For instance, the original trial might have measured the effectiveness of treatment on
cancer recurrence, while the trial extension results reported on cancer-related mortality or all-cause
mortality. Similar considerations can be applied to harms of treatment, whichmight continue,
regress, or emerge during the trial extension period.
Statistical Analysis
Analyses were descriptive. We calculated percentages, medians, ranges, and interquartile ranges
(IQRs). As this was a review of trials of a wide variety of interventions and end points there was no
rationale for pooling data across studies and we did not test any hypotheses. In categorizing
outcomes in the extended trial analyses as a significant benefit, a significant harm, a null result, or a
loss of a significant benefit, we were guided by the statistical analyses reported by authors of the
original and extended trials and did not reanalyze data. We did not assess the risk of bias of either the
original trials or the trial extension studies. However, we did notewhether posttrial interventions had
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been documented using routinely collected data and whether these had been included in trial
analyses.
Themain unit of analysis was the pairing of original and trial extension reports. Categorization
of trial outcomes was complicated by the fact that some trial extension studies reported several
analyses of different end points. We categorized extension study outcomes first by analyses and
report here all permutations of persistence, loss or development of benefits, and harms that were
seen across the pairs of trial reports. We then placed each pair of trial reports in a single category
using a hierarchy that represented the findings of greatest clinical importance.We used this hierarchy
to classify the studies (eTables 3 and 4 in the Supplement) and to provide clinical examples. The
hierarchy was structured as follows: statistically significant benefits of treatment observed in the trial
extension > statistically significant harms observed in the trial extension > null outcomes seen in the
trial extension > benefits of the intervention lost during the trial extension period > outcome analysis
was not according to randomization.
Results
From 2811 abstracts, we selected 309 full-text reports (Figure 1). One hundred sixty were excluded
for the reasons summarized in Figure 1. Of the 149 remaining studies, 36 duplicate reports were
excluded, yielding a total of 113 trial extension studies that met our inclusion criteria. Details of the
references for the pairs of reports (original trial and extension reports) are provided in eTable 3 and
eTable 4 in the Supplement.
Figure 1. PRISMA FlowDiagram for Inclusion of Studies Into Trial Extension Scoping Review
2 Additional records identified through
other sources
2811 Records after duplicates removed
2811 Records screened
309 Full-text articles assessed for eligibility
149 Articles considered eligible
113 Unique trials identified
36 Companion studies
4479 Records identified through database search
312 CINAHL
764 Cochrane trials
2410 Embase
993 MEDLINE
2502 Records excluded (reasons are not
mutually exclusive)
1400 Not a randomized clinical trial
31 Not a health outcome
957 Not a trial extension
249 No linked data
33 Duplicate records
160 Full-text articles excluded (reasons are
not mutually exclusive)
12 Not a randomized clinical trial
48 Not a trial extension
108 Not routinely linkable
9 Duplicate records
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Original Trials
Countries of Conduct
Forty-nine trials (43.4%) were conducted in Nordic countries, 26 (23.0%) in the United States, and
25 (22.1%) in the United Kingdom. The other countries are listed in Table 1.
Interventions and End Points
Themost common interventions were pharmaceutical products (47 trials [41.6%]), surgery
(including transplantation) (19 trials [16.8%]), and screening for disease (19 trials [16.8%]) (Table 1).
The end points studied in the original trials were most commonly mortality (67 trials [59.3%]),
cardiovascular disease events (blood pressure and lipid lowering treatments, and acute interventions
for myocardial infarction) (36 trials [31.9%]), and cancer (33 trials [29.2%]). However, the range of
interventions and end points was diverse (Table 1).
Trial Commencement Dates and Follow-up Periods
Most of the original trials took place in the 1980s and 1990s (Table 1). However, 6 (5.3%) commenced
before 1970, the oldest being a randomized placebo-controlled trial of the BCG vaccine, which
commenced in 1935.15 Follow-up periods of the original trials ranged from less than 1 year to more
than 20 years (Table 1).
Trial Extension Studies
The frequency of publication was highest in themost recent years of the study (Figure 2).
Extended Follow-up Times
Themedian (IQR) additional follow-up achieved by record linkage was 8 (4.5-13.8) years. The overall
range of additional follow-up varied from 1 to 50 years. The total follow-up times (original plus trial
extensions) ranged from 3 to 55 years, with a median (IQR) of 10.9 (7.3-19) years (Table 2).
Sample Sizes
The original trial sample sizes varied from 68 to 291 523 with a median (IQR) of 1224 (460-6595).
Sample sizes in the extension studies ranged from 47 to 247010, with a median (IQR) of 1222 (322-
5378).
Details of Analyses
Analyses were reported according to the original randomization in 104 of the trial extension reports
(92.0%) (Table 2). In 86 of the 99 reports that provided information (86.9%), results were reported
by intention to treat. Access to relevant intervention data after the trial concluded was reported in
18 studies (15.9%). This information was used in 7 studies (6.2%).
Clinical End PointsMeasured in theOriginal and Extended Trials
Mortality statistics (cause-specificmortality, all-causemortality, or both) were documented in 88 trial
extension studies (77.9%), compared with 67 of the original trials (59.3%) (Table 1 and Table 2).
Cancer end points (progression, recurrence, and cancer-relatedmortality) were reported in 41
extended studies (36.3%), compared with 33 of the original trials (29.2%) (Table 1 and Table 2).
Cardiovascular end points (cardiovascular events and deaths) were documented with similar
frequencies in the original (36 [31.9%]) and extended (37 [32.7%]) trial reports.
Research Ethics Approvals
Research ethics reviews were reported for 44 of the extension studies (38.9%). In 39 (34.5%), it
appeared that ethics review for the extension study had not been requested, and in 30 (26.5%) no
judgment could bemade.
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Table 1. Characteristics of the Original Trials Considered in the Scoping Reviewa
Study Characteristic No. (%)
Countries of originb
Nordic 49 (43.4)
United States 26 (23.0)
United Kingdom 25 (22.1)
Netherlands 10 (8.8)
Australia or New Zealand 10 (8.8)
Europe (other) 9 (8.0)
Canada 8 (7.1)
Other 4 (3.5)
Intervention type
Pharmaceutical 47 (41.6)
Surgery 19 (16.8)
Screening 19 (16.8)
Program (eg, general health, rehabilitation) 15 (13.3)
Diet 5 (4.4)
Psychological 5 (4.4)
Vaccine 4 (3.5)
Outcome type(s)b
Mortality 67 (59.3)
Cardiovascular 36 (31.9)
Cancer 33 (29.2)
Renal or diabetes 10 (8.8)
Osteoporosis 6 (5.3)
Infectious diseases 6 (5.3)
Illicit drug use 5 (4.4)
Transplant 5 (4.4)
Pregnancy 4 (3.5)
Other (various) 45 (39.8)
Decade(s) conductedb
2010s 2 (1.8)
2000s 35 (31.0)
1990s 74 (65.5)
1980s 42 (37.2)
1970s 11 (9.7)
1960s 1 (0.9)
1950s 3 (2.7)
1940s 1 (0.9)
1930s 1 (0.9)
Length of follow-up, y
<1 24 (21.2)
1-4 51 (45.1)
5-9 32 (28.3)
10-19 5 (4.4)
20-29 1 (0.9)
Sample size, No. (%) [range]
Quartile 1 28 (25) [68-462]
Quartile 2 28 (25) [462-1224]
Quartile 3 28 (25) [1224-6676]
Quartile 4 29 (26) [6676-291 523]
(continued)
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Details of Data Linkage
In 36 studies (31.9%) linkage involved only vital statistics registries. Health administrative data
documenting hospital discharges were used in 31 studies (27.4%), cancer registries in 28 (24.8%),
and specialized registries in 13 (11.5%). Data linkagemethods were described in 49 (43.4%) of the
studies. Of these, 33 (67.3%) reported using deterministic methods and 16 (32.7%) reported
probabilistic methods.
Categorization According to Analyses of StudyOutcomes
In total, the 113 trial extension reports provided details of 155 analyses of study outcomes. These are
categorized in Table 3. Seventy-four analyses (47.7%) identified statistically significant benefits in
the trial extension phase. In 21 of these (28.4%), benefits were significant only in this period. Null
results in both the original and extended trials were seen in 34 of the analyses (21.9%). Loss of
significant benefits of an intervention were seen in 12 analyses (7.7%). Statistically significant harms
were seen in 16 analyses (10.3%), and in 14 of these (87.5%), the harms were significant only in the
trial extension phase.
Categorization of Original and Extended Trial Reports
The 113 study pairs are categorized in eTable 3 and eTable 4 in the Supplement.
Studies That Found Long-termBenefits in the Trial Extension Phases
Sixty-one extension studies (53.9%) described a statistically significant long-term benefit of the
original trial intervention. In 42 of these (68.9%) the benefit appeared to be a continuation what was
seen in the original trial. Examples included a trial of thrombolysis in myocardial infarction
documenting a reduction in all-cause mortality at 1 year that persisted after 10 years16; a trial of
aggressive lowering of LDL cholesterol by statins that reduced the rate of revascularization by 30%
after 4 years, with a similar reduction still apparent after 7.5 years17; and a 55-year follow-up of the
Table 1. Characteristics of the Original Trials Considered in the Scoping Reviewa (continued)
Study Characteristic No. (%)
Used routinely collected data
Yes 42 (37.2)
No 71 (62.8)
Industry funded
Yes 49 (43.4)
No 49 (43.4)
Not stated 15 (13.3)
a Some extension studies combined the participants
frommultiple original randomized clinical trials.
b Categories are not mutually exclusive. Some
multicenter trials were conducted in more than 1
country and spannedmore than 1 decade.
Figure 2. Numbers of Trial Extension Studies Published Over Time
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JAMANetworkOpen | Statistics andResearchMethods Long-term Follow-up of Trial Participants by Linkage to Routinely Collected Data
JAMA Network Open. 2018;1(8):e186019. doi:10.1001/jamanetworkopen.2018.6019 (Reprinted) December 21, 2018 7/15
Downloaded from jamanetwork.com by BOND UNIVERSITY user on 01/29/2019
first trial of BCG vaccination that found a persistent level of protection against tuberculosis.15 In 21
studies (18.6%), statistically significant long-term benefits were seen only in the trial extension
phase. Four of these reported reductions in all-cause mortality,18-21 4 reported reductions in cardiac
events,21-24 and 2 reported reduced rates of cancer.25,26
Table 2. Characteristics of the Trial Extension Studies Included
in the Scoping Review
Study Characteristic No. (%)
Extension planned
Yes 19 (16.8)
No 44 (38.9)
Not stated or unclear 50 (44.2)
Length of posttrial follow-up, y
1-4 32 (28.3)
5-9 32 (28.3)
10-19 34 (30.1)
20-29 11 (9.7)
30-39 2 (1.8)
40-49 0
50-59 1 (0.9)
Total study follow-up, y
1-4 6 (5.3)
5-9 34 (30.1)
10-19 48 (42.5)
20-29 21 (18.6)
30-39 4 (3.5)
40-49 0
50-59 1 (0.9)
Sample size, No. (%) [range]
Quartile 1 28 (25) [47-322]
Quartile 2 28 (25) [322-1222]
Quartile 3 28 (25) [1222-5804]
Quartile 4 29 (26) [5804-427 010]
Analyzed according to original randomization
Yes 104 (92.0)
No 9 (8.0)
Outcome type(s)a
Mortality 88 (77.9)
Cancer 41 (36.3)
Cardiovascular 37 (32.7)
Transplant 6 (5.3)
Renal or diabetes 6 (5.3)
Osteoporosis 3 (2.7)
Other (various) 29 (25.7)
Authorship includes the original trial
investigators
Yes 105 (92.9)
No 6 (5.3)
Unclear 2 (1.8)
Industry funded
Yes 25 (22.1)
No 66 (58.4)
Not stated 21 (18.6)
a Categories are not mutually exclusive.
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Harms of Treatment in Trial Extension Phases
Thirteen of the trial extension reports (11.5%) described long-term harms of the interventions,
including 4 reports of long-term harms in patients randomized to pelvic or chest radiotherapy for
colorectal, endometrial, or breast cancer: venous and arterial thrombosis, adhesions, intestinal
fistulae, and second cancers.27-29 There were 2 reports of possible long-term harms of estrogens:
atrial fibrillation in postmenopausal women and benign lesions of the cervix in female offspring of
womenwho received them in pregnancy.30,31 Two reports described possible harms of blood
transfusion: reduced survival in trial participants who received buffy coat–depleted red cells and in
recipients of autologous red cell transfusions.32,33
TrialsWith Null Results
Twenty-two of the trial extension reports (19.5%) found no significant difference in outcomes
between intervention and control groups. Examples included the following: no increase in
cardiotoxicity when epirubicin replacedmethotrexate in chemotherapy for breast cancer34; a
reduction in cardiac events, but not overall survival, in high-risk elderly patients treated with
pravastatin35; a trial of BCG vaccine in patients with bladder cancer finding no improvement in overall
survival compared with mitomycin C despite promising results in the original trial36; and a follow-up
study of childrenwith in utero exposure to progestogen that did not lead to long-term harms for child
health and development.37
Loss of Intervention Benefits
Intervention benefits seen in the original trial were lost in the trial extension phase in 6 studies
(5.3%). Examples included the following: after an early advantage of mycophenolate mofetil over
azathioprine in graft rejection in the first 6months after renal transplantation, the extension analysis
found no differences in long-term patient or graft survival38; an early reduction in cardiac eventswas
observed in patients who received early aggressive (rather than conservative) intervention for
unstable angina, but long-term follow-up found no reduction in all-cause mortality and
cardiovascular deaths39; and a significant reduction in breast cancer mortality in a mammography-
screened group in the first 10 years after diagnosis, but not thereafter.40
Table 3. Summary of Results of Trial Extension Studiesa
Patterns of Outcomes Reported in the Trial Extension Study No. (%) Comments
Significant benefits of intervention seen in original and
extended trial using the same end points as in the original
trial
42 (27.1) Using the same end point measures,
but defined using administrative data
in the extended trial
Significant benefits of intervention seen in original and
extended trial with different end points in the extended trial
11 (7.1) Different end points could be, for
example, cardiovascular deaths rather
than cardiovascular events
Significant benefits of intervention seen only in the extended
trial using the same end points as in the original trial
6 (3.9) Using the same end point measures,
but defined using administrative data
in the extended trial
Significant benefits of intervention seen only in the extended
trial using different end points in the extended trial
15 (9.7)
Equivalence of intervention seen in original and extended
trial
20 (12.9) Using the same end point measures,
but defined using administrative data
in the extended trial
Equivalence of intervention seen in original and extended
trial with different end points in the extended trial
14 (9.0)
Significant benefits of intervention seen in the original trial
were no longer significant in the extended trial
12 (7.7) Using the same end point measures,
but defined using administrative data
in the extended trial
Significant harms of intervention seen only in the extended
trial
14 (9.0)
Significant harms seen in original and extended trial 2 (1.7)
Outcomes in the extended trial were not analyzed according
to randomization
19 (12.3) For example, observational study of
treated cohort only
a Includes a total of 155 analyses from 113
study reports.
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Discussion
Against a background of more than 20000 randomized trials registered each year, this scoping
review identified a small number of reports of trials that had been extended by linkage to registry and
administrative data to evaluate long-term outcomes of trial interventions.41 Nordic countries were
overrepresented in this literature, a testament to their commitment to conducting trials and the
value placed onmaintaining high-quality registries that enable data linkage.42
The versatility of trial extension by data linkage is illustrated here by thewide variety of findings.
These include observations of a possible legacy effect of statin use43; a 55-year protective benefit of
BCG vaccination15; evidence of cancer prevention with hepatitis B virus and human papillomavirus
vaccines44,45; confirmation that in-utero exposure to progestogens does not lead to child health or
developmental problems37; and quantification of an increased risk of secondmalignancies long after
radiotherapy for breast or endometrial cancer.29,46 We highlight these studies to illustrate the value
of trial extension using linkage to routinely collected data and do not claim that these study findings
are definitive estimates of the benefits and harms of the interventions.
Because of the heterogeneity of topics, we did not performmeta-analyses of trial extension
outcomes. But this has been done recently by Nayak and colleagues47 while exploring posttrial statin
legacy effects on all-cause mortality. They suggest that most effect is seen in primary
prevention studies.
Our data showed an increasing rate of publication of trial extension studies, albeit from a low
base. Growing awareness of this approach and greater availability of linkable registry data may lead
tomore extension studies being planned as part of the original trials. Increasing access to
randomized trial data through developments such as the AllTrials movement may encourage
independent groups to perform participant data linkage.48 This provides an opportunity to both
reproduce the original trial analyses and determine long-term outcomes, which was not done in any
of the studies reviewed here.
The reports we retrieved did not document the costs of follow-up of trial participants; however,
record linkage is inexpensive. The cost of the extension of theWest of Scotland Coronary Prevention
trial (N = 6595) was stated to be £15 000 ($19 600), a fraction of the cost of the original trial.49 In
their recent review of long-term follow-up of large randomized clinical trials published between
2006 and 2017, Llewellyn-Bennett and colleagues4 found that costs varied from thousands of dollars
using record-linkage tomillions of dollars with clinical follow-up.
Methodological and Reporting Issues
It was not clear how often trial extension had been planned as part of the original trial. This raises the
possibility of post hoc selection of study end points and/or analyses, an important source of bias.50
In most of the extension studies, the end points were those used in the original trials, except that
they were quantified using routinely collected data, such as vital statistics, cancer registries, and
hospital discharge diagnoses. While posttrial analyses of linked data are observational, we believe
they have clear advantages over traditional studies of long-term outcomes because the original
exposure was determined by randomization. The initial randomization stepminimizes selection bias,
andmost trials demonstrate good control at baseline for confounders, but the long follow-up periods
providemany opportunities for treatment switches and co-interventions. Our data show that these
are usually undocumented. This limits capacity to adjust for time-dependent variables, which can
distort estimates of intervention effectiveness.
We did not assess the risk of bias in the trials included in the review, which would have been
necessary if we were conducting meta-analyses. In their recent systematic review of posttrial
follow-upmethodology in large randomized clinical trials, Llewellyn-Bennett and colleagues4 found
a generally low risk of bias and similar attrition rates with different follow-upmethods. However, bias
assessment appears to have been limited to the randomized phase of the trial andmay not have
taken account of time-varying confounding in the posttrial phase.
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Some informationwas incompletely reported in the studies we reviewed, includingwhether the
study was preplanned, the quality and accuracy of the data used, and the type and success of the
linkagemethod. It was sometimes unclear whether ethics approval had been specifically sought for
the extension study or whether specific funding sources had been secured for the long-term study.
It is beyond the scope of this article to provide opinions on all standards that should apply to this
type of work, but we can identify several key topics. Important activities to be included in the original
trial planning include (1) ethics approval for data linkage and analysis and inclusion of this procedure
in the original consent forms and (2) awareness by institutional ethics committees of the need to
preserve trial records, including information required for data linkage. The value of trial extension
reports could be improved by adherence to reporting standards. The RECORD (Reporting of Studies
Conducted Using Observational Routinely-Collected Data) collaborative provides guidance and a
checklist developed from the original STROBE (Strengthening the Reporting of Observational Studies
in Epidemiology) guidelines.51 In addition, there are plans to develop a CONSORT (Consolidated
Standards of Reporting Trials) extension for randomized clinical trials using cohorts and routinely
collected health data.52
Accuracy of Routinely CollectedData
Administrative data are usually limited tomajor events that lead to hospitalization, death, and
notifiable diseases. In such cases, the accuracy of routinely collected data is assumed to be high. It
was notable that none of the studies we reviewed took the opportunity to calibrate the initial trial
end point frequencies against contemporaneous administrative data before using the latter to
evaluate long-term outcomes. Changing coding practices or inaccuracies and alterations in disease
definitions can affect interpretation. Administrative records generally lack information on vital signs
and laboratory and diagnostic test results.53,54 Some billing data for community care include
diagnostic information (eg, in Ontario, Canada), but this appears uncommon.55 Data on prescribing
or dispensing of medicines are usually available and are accurate, but access to linkable routine
laboratory data is variable.54 Important clinical information, such as body weight, smoking history,
and blood pressure are usually absent from administrative data.56 Thus, some trial extension work
will be limited by lack of access to accurate clinical data with which to explain variations in trial
outcomes.
Limitations
It is likely that our literature searchmissed studies. However, we think that those we selected are
representative of the wider literature. Our difficulty with searching underscores the need for
agreement on terminology to ensure consistent indexing of relevant studies. As noted in the
preceding paragraphs, we did not reanalyze the aggregate data or assess the accuracy of the authors’
statistical analysis.We did not critically appraise the articles. In categorizing long-term outcomes, we
used an arbitrary approach based on authors’ reported statistical analyses, and our categories
probably overlap. However, our conclusions are broad, based on descriptive analyses, and unlikely to
be sensitive to misclassification.
Conclusions
Trial extension by linkage to routinely collected data is a versatile, underused approach that may add
critical insights beyond those of the original trial. Some beneficial and harmful outcomes of
interventions are captured only in the extension phase of randomized trials.
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